The following stories appear in full on today's Vidyya Medical News Service Web site.
Under-diagnosis of peripheral arterial disease (PAD) is likely to serve as a barrier to effective prevention of myocardial infarction and stroke, the main cardiovascular risks associated with PAD, according to the PARTNERS program data released Sunday at the 73rd annual meeting of the American Heart Association.
Speaking of heart disease, get a synopsis of three studies published in the 07 November Circulation: Journal of the American Heart Association examine the role of infections and inflammation in heart attacks.
Another day, another drug, another new indication. The US Food and Drug Administration has approved Zyprexa® (olanzapine) for the long-term therapy and maintenance of treatment response of schizophrenia. Zyprexa is the first of the newer generation of antipsychotics, known as "atypicals," to prove its long-term effectiveness in the schizophrenic population. Zyprexa (olanzapine) is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. Get the full prescribing information in today's issue.
When it comes to health information, the same few stories jump from medical journal to newspaper to television. The past week's biggest stories were about phenylpropanolamine, early puberty, cellular telephones, penicillin and that old favorite--heart attack and exercise. Get a brief rundown of the most popular stories with a short article in today's issue.
As always, we hope you enjoy the issue.